ABSTRACT
Background High ovarian cancer mortality rates motivate the development of effective and patient-friendly diagnostics. Here, we explored the potential of molecular testing in patient-friendly samples for ovarian cancer detection.
Patients and methods Home-collected urine, cervicovaginal self-samples, and clinician-taken cervical scrapes were prospectively collected from 54 patients diagnosed with a highly suspicious ovarian mass (benign n=25, malignant n=29). All samples were tested for nine methylation markers, using quantitative methylation-specific PCRs that were verified on ovarian tissue samples, and compared to unpaired patient-friendly samples of 110 healthy controls. Copy number analysis was performed on a subset of urine samples of ovarian cancer patients by shallow whole-genome sequencing.
Results Three methylation markers were significantly elevated in full void urine of ovarian cancer patients as compared to healthy controls (C2CD4D, p=0.008; CDO1, p=0.022; MAL, p=0.008), of which two were also discriminatory in cervical scrapes (C2CD4D, p=0.001; CDO1, p=0.004). When comparing benign and malignant ovarian masses, GHSR showed significantly elevated methylation levels in the urine sediment of ovarian cancer patients (p=0.024). Other methylation markers demonstrated comparably high methylation levels in benign and malignant ovarian masses. Cervicovaginal self-samples showed no elevated methylation levels in patients with ovarian masses as compared to healthy controls. Copy number changes were identified in 4 out of 23 urine samples of ovarian cancer patients.
Conclusion Our study revealed increased methylation levels of ovarian cancer-associated genes and copy number aberrations in the urine of ovarian cancer patients. Our findings support continued research into urine biomarkers for ovarian cancer detection and highlight the importance of including benign ovarian masses in future studies to develop a clinically useful test.
HIGHLIGHTS
Ovarian cancer is often diagnosed at an advanced stage with a poor prognosis
We studied the potential of molecular testing in different types of patient-friendly material for ovarian cancer detection
Elevated methylation of ovarian cancer-associated genes can be measured in cervical scrapes and urine
Copy number aberrations are detectable in urine of ovarian cancer patients
DNA-based testing in cervical scrapes and urine could aid ovarian cancer diagnosis upon further development
GRAPHICAL ABSTRACTCreated with BioRender.com.
Competing Interest Statement
Conflict of interest statement RS has a minority share in Self-screen B.V., a spin-off company of Amsterdam UMC, location VUmc. Self-screen B.V. holds patents and products related to the work. RS and FM are co-inventors on multiple patents related to methylation markers and cfDNA analysis, respectively. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.
Funding Statement
This research was funded by the CCA Foundation and Maarten van der Weijden Foundation, who provided financial support for the conduct of the research and had no role in conducting the research and preparation of the manuscript. RvdH was funded by the Weijerhorst Foundation. NM and FM were funded by the Dutch Cancer Society (grant number KWF: 12822).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the VU University Medical Center gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data and code availability
The sequencing dataset generated and analyzed during the current study is available in the European Genome-Phenome Archive repository, under accession number EGAD00001010848. The DNA methylation dataset generated and analyzed during this study is available from the corresponding author on reasonable request.
Glossary
- cfDNA
- cell-free DNA
- Cq
- quantification cycle
- FFPE
- formalin-fixed paraffin-embedded
- HGSOC
- high grade serous ovarian cancer
- hrHPV
- high-risk human papillomavirus
- qMSP
- quantitative methylation-specific PCR
- SCNA
- somatic copy number aberrations
